An independent researcher, Douglas Yao, has announced the invention of PAC-832, a new drug candidate for Alzheimer’s disease, which he claims to have designed and synthesized in a chemistry laboratory built in his garage. Yao stated in a recent tweet, > "This vial contains a new drug called PAC-832, which I recently invented to treat Alzheimer’s disease. It is the world’s first selective GalR1 antagonist." The announcement has garnered significant attention due to the unconventional nature of its development.
PAC-832 is described as the "world's first selective GalR1 antagonist," targeting the galanin receptor 1, which plays a role in regulating neurotransmitters like acetylcholine in the brain. According to Yao, the drug exhibits sub-micromolar potency for GalR1 and over 30 times selectivity over GalR2/3. Early tests in mice reportedly showed significant improvements in memory, along with favorable properties such as low toxicity, excellent manufacturability, and the ability to cross the blood-brain barrier.
Douglas Yao, who holds a Ph.D. in computational biology from Harvard, has published in prominent scientific journals including Nature Biotechnology and Nature Genetics. He states that his approach to drug discovery is inspired by the methods of Paul Janssen, emphasizing rapid synthesis and testing, augmented with modern biotech tools and AI for design. Yao is funding this project with his personal savings, aiming to significantly reduce the typical costs associated with preclinical drug development.
The conventional drug development process is a lengthy and expensive endeavor, typically spanning 10-15 years and costing billions of dollars, involving rigorous stages from discovery and preclinical research to multi-phase clinical trials and stringent FDA review. Independent researchers or small labs face considerable challenges in meeting these regulatory and scientific requirements, which demand access to specialized equipment, substantial funding, and expertise in regulatory affairs. Alzheimer's drug development is particularly challenging, known for its high failure rates in clinical trials.
Yao indicated that PAC-832 still has a long road ahead to reach FDA approval, acknowledging the notoriously high clinical failure rate for Alzheimer's treatments. He is currently preparing PAC-832 for Phase 1 clinical trials, which he anticipates starting within a year. If successful, PAC-832 would be the first GalR1 antagonist to enter clinical development.
